U.S. Senator Elizabeth Warren has asked antitrust regulators to scrutinize a $16.5 billion deal in which Novo Nordisk's ...

Sen. Elizabeth Warren (D-MA) is calling on the Federal Trade Commission to carefully evaluate Novo Nordisk Foundation's ...

U.S. Sen. Elizabeth Warren has asked the Federal Trade Commission “closely scrutinize” a $16.5 billion deal in which Novo ...

Concerns are rising as Novo Nordisk's $16.5 billion bid to acquire Catalent faces scrutiny from the FTC. Critics argue the ...

Senate Democrat Elizabeth Warren urges the Federal Trade Commission to closely scrutinize a proposed merger between Novo Nordisk and contract development and manufacturing organization Catalent, ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

As Novo Holdings hopes to close its $16.5 billion acquisition of CDMO Catalent by the end of the year, the deal is facing a fresh round of lawmaker scrutiny. | In a letter to the chair of the U.S.

Eli Lilly has called on financial regulators to look into the antitrust implications of Novo Holdings' purchase of Catalent and the sale of three manufacturing facilities to Novo Nordisk.

Novo Holdings will acquire Catalent for $63.50 a share in cash.

Earlier this week, Novo Nordisk disclosed plans to acquire healthcare manufacturer Catalent (CTLT) at an enterprise value of $16.5 billion. Catalent operates over 50 manufacturing facilities ...

CONTEXT Novo Holdings, the investment firm that has a controlling interest in Novo Nordisk, signed a $16.5 billion deal to buy Catalent in February to boost Wegovy supply. The deal is expected to ...